Full-Time

Head – Market Access and Patient Services

Confirmed live in the last 24 hours

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

51-200 employees

Develops treatments for neurodegenerative diseases

Biotechnology
Healthcare

Senior, Expert

No H1B Sponsorship

Remote in USA

Candidates must reside in the United States and in a state where Amylyx currently does business. The role requires traveling to the corporate location in Cambridge, MA several times a year.

Category
Strategic Account Management
Sales & Account Management

You match the following Amylyx Pharmaceuticals's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Undergraduate degree required, MBA and/or relevant post graduate qualifications preferred
  • 15+ years of pharmaceutical industry experience and minimum of 10 years in market access leadership positions, including building and leading payer account teams
  • Established network of Payer and PBM relationships
  • Prior people management experience – especially managing payer account teams
  • Track record successfully negotiating access for prescription products in competitive therapeutic areas in the US
  • Possess strong ‘executive presence’ and excellent communication skills
  • Demonstrated ability to lead and influence in rapidly changing environment
  • Travel - Position requires up to 30% travel
Responsibilities
  • Serve as the primary market access point of contact for the US region; ensure launch and pipeline assets are supported.
  • Build the access strategy, payer account, field reimbursement, patient services and specialty pharmacy distribution teams that will be needed to ensure a successful launch of Avexitide®, for Post Bariatric Hypoglycemia
  • Champion pricing and reimbursement requirements throughout organization and ensure alignment between all stakeholders internally; this includes identifying payer unmet needs, assessing pricing potential, identifying access challenges and ways to overcome, overseeing tactical execution plans, supporting payer negotiations as needed, etc.
  • Be accountable for the development of US market access deliverables, negotiation strategies, and national/regional market access tactics to secure price and reimbursement
  • Collaborate with internal stakeholders (Marketing, Medical Affairs, Regulatory, Legal and Finance), to ensure that plans are fit-for-purpose
  • Design a tailored patient support program to enable broad and timely patient access.
  • Provide Market Access perspectives in support of business development initiatives
  • Develop pre- and post-approval engagement strategies.
  • Initiate, maintain, and tactfully influence relationships with various medical and non-medical stakeholders.
  • Mentor individuals on the US Market Access and Reimbursement team • Actively contribute to the annual brand planning, forecasting, and budgeting process.
  • Other duties as assigned.
Desired Qualifications
  • MBA and/or relevant post graduate qualifications preferred
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.

Company Size

51-200

Company Stage

IPO

Total Funding

$166.7M

Headquarters

Cambridge, Massachusetts

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Gubra enhances treatment efficacy for neurodegenerative diseases.
  • Acquisition of avexitide diversifies Amylyx's therapeutic portfolio.
  • HELIOS trial shows AMX0035's potential for treating Wolfram syndrome.

What critics are saying

  • Departure of key personnel may disrupt clinical development.
  • Failure of PHOENIX trial impacts investor confidence.
  • Low stock offering price suggests potential financial instability.

What makes Amylyx Pharmaceuticals unique

  • Amylyx focuses on neurodegenerative diseases like ALS and Alzheimer's.
  • AMX0035 is a promising drug for ALS and Alzheimer's treatment.
  • Amylyx engages in community awareness campaigns for neurodegenerative diseases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

10%

2 year growth

11%
Business Wire
Feb 18th, 2025
Nura Bio Expands Leadership Team with C-Suite Appointments

Lahar Mehta, M.D. Lahar Mehta, M.D., joins Nura Bio from Amylyx Pharmaceuticals, where he was Senior Vice President/Head, Global Clinical Development, leading clinical development and clinical pharmacology activities across several indications including amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and Wolfram syndrome.

ETF Daily News
Jan 13th, 2025
Amylyx Pharmaceuticals Enters Underwriting Agreement for Public Offering

On January 10, 2025, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced its entry into an underwriting agreement with Leerink Partners LLC for the issuance and sale of 17,142,857 shares of its common stock at a price of $3.50 per share.

Business Wire
Jan 11th, 2025
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,142,857 s

CityBiz
Jan 6th, 2025
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

Amylyx Pharmaceuticals appoints Dan Monahan as Chief Commercial Officer.

TipRanks
Dec 30th, 2024
Amylyx Partners with Gubra for GLP-1 Antagonist

Amylyx partners with Gubra for GLP-1 antagonist.